Company: DHR
Filing Date: 2025-03-26
Form Type: ARS
Source: 0000313616-25-000085
Chunk: 75

Company: DANAHER CORP /DE/
Filing Date: 2025-03-26
Form: ARS
Chunk 75
---
85 basis points • 2024 impairment charges related to a trade name in each of the Life Sciences and Diagnostics segments, net of 2023 impairment charges related to technology-based intangible assets in the Diagnostics segment and technology-based intangible assets and other assets in the Biotechnology segment. Refer to Note 10 to the accompanying Consolidated Financial Statements for additional information regarding the impairments - 75 basis points • Full year 2024 loss on the termination of a commercial arrangement in the Diagnostics segment - 25 basis points • 2023 gain from the resolution of a litigation contingency in the Life Sciences segment - 5 basis points 2024 vs. 2023 operating profit margin comparisons were favorably impacted by: • Acquisition-related transaction costs deemed significant, settlement of pre-acquisition share-based payment awards and fair value adjustments to inventory in 2023, net of acquisition-related fair value adjustment to inventory in 2024, in each case related to the acquisition of Abcam plc (“Abcam”) - 30 basis points • Increased leverage and productivity in the Company’s operational and administrative cost structure, net of lower 2024 core sales and the impact of product mix - 20 basis points 37

Business Segments Sales by business segment for the years ended December 31 are as follows ($ in millions): 2024 2023 2022 Biotechnology $ 6,759 $ 7,172 $ 8,758 Life Sciences 7,329 7,141 7,036 Diagnostics 9,787 9,577 10,849 Total $ 23,875 $ 23,890 $ 26,643 For information regarding the Company’s sales by geographical region, refer to Note 5 to the Consolidated Financial Statements. BIOTECHNOLOGY The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Company’s solutions support a broad range of biotherapeutics including monoclonal antibodies, recombinant proteins, replacement therapies such as insulin and vaccines, as well as novel cell, gene, mRNA and other nucleic acid therapies. Biotechnology Selected Financial Data Year Ended December 31 ($ in millions) 2024 2023 2022 Sales $ 6,759 $ 7,172 $ 8,758 Operating profit 1,685 1,909 3,